Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous, Charlotte Green, Thomas Jackson, Michael Ferguson, Janet M. Lord*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

Original languageEnglish
Pages (from-to)1403-1415
Number of pages13
JournalDrug Discovery Today
Issue number8
Publication statusPublished - Aug 2020

Bibliographical note

Funding Information:
C.E. and C.G. are funded by the UK SPINE Knowledge Exchange network . We thank Teresa O’Leary for her help in identifying geroscience-informed trials in the USA. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social care.

Publisher Copyright:
© 2020 The Authors

Copyright 2020 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Treating age-related multimorbidity: the drug discovery challenge'. Together they form a unique fingerprint.

Cite this